SEC Form 4 · accession 0001209191-17-034923
INTEGRA LIFESCIENCES HOLDINGS CORP · IART
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart Essig
Director
Period of report
May 22, 2017
Accepted (ET)
May 24, 2017 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000917520
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 22, 2017 | M | 44,571 | $17.45 | A | 1,973,335 | D | |
| Common StockF3 | May 22, 2017 | S | 44,571 | $48.0098 | D | 1,928,764 | D | |
| Common Stock | May 23, 2017 | M | 68,780 | $17.45 | A | 1,997,544 | D | |
| Common Stock | May 23, 2017 | M | 95,429 | $17.45 | A | 2,092,973 | D | |
| Common StockF4 | May 23, 2017 | S | 95,429 | $48.0139 | D | 1,997,544 | D | |
| Common Stock | May 23, 2017 | A | 4,587 | $0.00 | A | 2,002,131 | D | |
| Common Stock | May 23, 2017 | A | 1,564 | $0.00 | A | 2,003,695 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6,F5 | $17.45 | May 22, 2017 | M | 44,571 | D | — | Dec 18, 2017 | Common Stock | 44,571 | 372,989 | D |
| Non-Qualified Stock Option (right to buy)F5 | $17.45 | May 23, 2017 | M | 68,780 | D | — | Dec 18, 2017 | Common Stock | 68,780 | 304,209 | D |
| Non-Qualified Stock Option (right to buy)F5 | $17.45 | May 23, 2017 | M | 95,429 | D | — | Dec 18, 2017 | Common Stock | 95,429 | 208,780 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
- F2On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4.
- F3The price shown above represents the weighted average price of the shares sold. The range of sale prices was $48 to $48.10.
- F4The price shown above represents the weighted average price of the shares sold. The range of sale prices was $47.90 to $48.14.
- F525% of the option grant vested on 12/18/2008 (the first anniversary of the grant date of 12/18/2007), and the remaining 75% vested monthly thereafter over 36 months.
- F6This stock option was previously reported as covering 208,780 shares of common stock at an exercise price of $34.90 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016.